Nurses' perceptions on the usability of the Hyrimoz^® Sensoready^® autoinjector device.

ABSTRACT:

Background

Hyrimoz^® (Sandoz adalimumab biosimilar) became available in the USA in July 2023, and is administered subcutaneously using a pre-filled autoinjector device, the Hyrimoz Sensoready^® pen. As nurses are often responsible for training patients in the use of autoinjectors, this survey aimed to assess gastroenterology nurses' perceptions of autoinjectors in the USA.

Methods

Eligible participants included nurses in the USA currently working within a gastroenterology practice with experience managing inflammatory bowel disease and with reference to adalimumab, Humira^®. Participants were sent the Hyrimoz Sensoready pen, which was opened during a web-assisted telephone interview. The survey assessed the importance of specified autoinjector d

SUBMITTER: Both C 

PROVIDER: S-EPMC12463172 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature